Drug intelligence / Profile preview

MILGa

Development stage: Unknown
Lead developer: Minomic International
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MILGa is a 67Gallium-labeled chimeric monoclonal antibody (MIL-38) developed by Minomic International. It is designed as an imaging agent to detect prostate, bladder, and pancreatic cancers by assessing its safety, sensitivity, and specificity. The antibody targets Glypican-1, a protein found on the surface of certain cancer cells. This agent is being evaluated as both a diagnostic imaging tool and has potential therapeutic applications.

Brand names: MILGa
Other names: Milga

Targets

GPC1 (Glypican-1)

Beyond the preview

Go deeper on MILGa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MILGa.

Explore the full profile